Last reviewed · How we verify
NCT06987370
SFRT and SCART in Radiotherapy for Bone Metastases With Soft Tissue
NA trial testing Conventional Radiotherapy (CRT) in Bone Metastases in Subjects With Advanced Cancer in 90 participants. Currently enrolling.
30 November 2027
Quick facts
| Lead sponsor | Shandong Cancer Hospital and Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 1 June 2025 |
| Primary completion | 30 November 2027 |
| Estimated completion | 30 November 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Conventional Radiotherapy (CRT)
- SCART (Stereotactic Central Ablative Radiation Therapy ) /SFRT（Spatially Fractionated Radiation Therapy ）
Conditions studied
- Bone Metastases in Subjects With Advanced Cancer — all drugs for Bone Metastases in Subjects With Advanced Cancer →
Sponsor
Shandong Cancer Hospital and Institute
Who can join
Adults 18 to 75, any sex, with Bone Metastases in Subjects With Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, controlled, prospective phase II, two-arm clinical study designed to evaluate the efficacy and safety of using either Spatially Fractionated Radiotherapy (SFRT) or Stereotactic Central Ablative Radiotherapy (SCART) for treating the soft tissue components of malignant bone metastases. The study plans to enroll 90 patients with bone metastases accompanied by soft tissue formation, who will be randomized in a 2:1 ratio to the SFRT/SCART group or the conventional radiotherapy (CRT) group.The primary endpoint is the objective response rate (ORR). Tumor response to treatment will be assessed every 12 weeks (±7 days) according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Secondary endpoints include pain relief rate, progression-free survival (PFS), and safety. In addition, adverse events (AEs) will be monitored throughout the study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Efficacy and safety evaluation of radiotherapy approach based on spatially fractionated radiotherapy and stereotactic core ablative radiation therapy technologies for bone metastatic malignant tumors with soft tissue formation: A randomized controlled phase II trial.
Kou Y, Xu K, Zhu K, Jiang S, et al · · 2025 · PMID 41477287 · DOI 10.1002/pro6.70036
Verify or expand the search:
- PubMed search for NCT06987370
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bone Metastases in Subjects With Advanced Cancer
Currently open trials in the same condition.
- NCT07197645 — Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain · Phase 1 · recruiting
- NCT07171996 — Research on the Optimization of Treatment for Spinal Metastases With Radioactive Particle Implantation Using TPS and Mec · NA · recruiting
Other Shandong Cancer Hospital and Institute trials
Trials by the same sponsor.
- NCT07408505 — Nano-Megestrol Acetate for Cancer Cachexia in Advanced Pancreatic Cancer · NA · recruiting
- NCT07403370 — Olanzapine Dose Comparison for the Prevention of HER-INV: A Network Meta-Analysis · recruiting
- NCT07376174 — The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted T · recruiting
- NCT07333274 — Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Adva · Phase 3 · recruiting
- NCT07274774 — SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06987370 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shandong Cancer Hospital and Institute
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06987370.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing